Event Highlights
News from Bayer
November 15, 2021
Not intended for U.S. and UK Media
Bayer extends clinical development program for finerenone with Phase III study in children and adolescents with chronic kidney disease
November 11, 2021
Not intended for U.S. and UK Media
New Phase III study to investigate expanded use of vericiguat in patients with chronic heart failure with reduced ejection fraction
November 10, 2021
Not intended for U.S. and UK Media
Bayer Submits Aflibercept for regulatory approval in the EU and Japan for Retinopathy of Prematurity in premature babies
Discover More Investor Resources
